Salidroside is the main active compound of golden root, a plant sold as a dietary supplement for fatigue, stress and endurance, and now also made by fermentation. Better endurance and faster recovery from hard training are the best-established effects. Mood steadiness under stress is plausible but unsettled. Lifespan, brain, liver, kidney and cancer claims rest on animals. It is a low-cost, low-risk, short-term experiment. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 70–85 mg/dL | Detects additive glucose lowering, the main metabolic risk |
| Fasting insulin | 2–5 µIU/mL | Tracks the insulin-sensitivity claim directly |
| Glycated hemoglobin | 4.8–5.4% | Confirms that any glucose shift is sustained, not a one-off reading |
| Alanine and aspartate aminotransferase | 10–26 U/L (women), 10–30 U/L (men) | Liver safety, and the organ where the fatty-liver claim would show |
| High-sensitivity C-reactive protein | < 0.5 mg/L | The inflammation mechanism claimed for the compound |
| Estimated glomerular filtration rate | > 90 mL/min/1.73 m² | Clearance route for the compound; falling values raise exposure |
| Heart-rate variability | No established salidroside target; track change from the individual's own 7-day baseline | Objective proxy for stress-axis load and recovery |
| Morning cortisol | 10–15 µg/dL | The stress-hormone axis the compound is claimed to modulate |
Cadence: Baseline before starting; glucose and insulin rechecked at 4 weeks, the full panel at 12 weeks, then every 6–12 months on continued use. Daily fasting-glucose self-checks for the first 2 weeks apply to anyone taking glucose-lowering medication.